These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 21975200

  • 1. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.
    Neurology; 2011 Nov 01; 77(18):1684-90. PubMed ID: 21975200
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
    Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N.
    Mult Scler; 2011 May 01; 17(5):541-9. PubMed ID: 21148262
    [Abstract] [Full Text] [Related]

  • 3. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 01; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 4. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 01; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 5. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 6. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 26; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 7. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA, Fisher E, Lee JC, Duda JT, Simon J.
    Mult Scler; 2000 Dec 26; 6(6):365-72. PubMed ID: 11212130
    [Abstract] [Full Text] [Related]

  • 8. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct 26; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 9. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 10. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
    Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.
    Ann Neurol; 2013 Jan 26; 73(1):95-103. PubMed ID: 23378325
    [Abstract] [Full Text] [Related]

  • 11. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 26; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 12. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 26; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 13. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA, Rivera VM.
    Curr Med Res Opin; 2010 Apr 26; 26(4):827-38. PubMed ID: 20121658
    [Abstract] [Full Text] [Related]

  • 14. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R.
    Eur Neurol; 2004 Apr 26; 51(1):15-20. PubMed ID: 14631124
    [Abstract] [Full Text] [Related]

  • 15. Combined MRI lesions and relapses as a surrogate for disability in MS.
    Ebers GC, Scalfari A, Daumer M, Lederer C.
    Neurology; 2012 Apr 24; 78(17):1367; author reply 1367. PubMed ID: 22529206
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 24; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 17. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2008 Nov 24; 60(6):279-84. PubMed ID: 18824855
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Lancet Neurol; 2011 Apr 24; 10(4):338-48. PubMed ID: 21397567
    [Abstract] [Full Text] [Related]

  • 19. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
    Mult Scler; 2010 Apr 24; 16(4):450-4. PubMed ID: 20150398
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov 24; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.